195
Analysis of the impact of high-dose atorvastatin on cardiovascular mortality in outpatient care, free with a doctor’s prescription, under the “fight against cardiovascular diseases” program in the Khanty-Mansi autonomous okrug – Yugra (Regional Experience)
Mortality from diseases of the circulatory system remains the first cause in the structure of mortality of people of working age and older, where the main cause of complications is atherosclerotic disease, for the correction of which lipid-lowering drugs are used. THE AIM of the study was to assess the effect of the use of high doses of atorvastatin in drug therapy on mortality from dis- eases of the cardiovascular system. MATERIAL AND METHODS. The register of dispensed prescriptions patients that received medicines for free for the period from 2021 to 2023, as well as data on the death of patients from cardiovascular diseases (death certificates) for the same period were used. The construction of variation series and the assessment of the reliability of relative numbers based on the Student’s double T-test were carried out. Results. The reliability of impact on mortality high doses of atorvastatin was established in the group of women from 49 to 59 years old and men from 60 to 74 years old. CONCLUSION. In order to implement the «Fight against cardiovascular diseases» program, this study can be used in making management decisions and organizing events that affect the mortality of the population from diseases of the cardiovascular system.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kasianova E. V., Urvantseva I. A., Klimshina T. K., Kurakov D. A. Analysis of the impact of high-dose atorvastatin on cardiovascular mortality in outpatient care, free with a doctor’s prescription, under the “fight against cardiovascular diseases” program in the Khanty-Mansi autonomous okrug – Yugra (Regional Experience) // Pharmacoeconomics: theory and practice. - 2025. - Vol.13, №4. P. 5-9 DOI: https://doi.org/10.30809/phe.4.2025.1
Comments0